ArticleEye (London, England)2017
Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival.
Article in Eye (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 62 citations in OpenAlex.
- Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.Nature medicine · 2025Trial
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.The New England journal of medicine · 2022Trial
- Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.Journal for immunotherapy of cancer · 2021Trial
- Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.The oncologist · 2021Trial
- Recurrence of Non-Melanoma Skin Cancers in the Head and Neck Area-A Single-Center Retrospective Analysis.Journal of clinical medicine · 2026Article
- A Systematic Review and Meta-Analysis of Ocular and Periocular Basal Cell Carcinoma with First-Time Description of Dermoscopic and Reflectance Confocal Microscopy Features of Caruncle Basal Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2025Review
- Article
- The Value of Orbital Exenteration for Eyelid Sebaceous Carcinoma in Stages II to IV: A Cohort Study of 78 Patients.Investigative ophthalmology & visual science · 2025Article
- Factors influencing delayed presentation of periorbital carcinoma requiring orbital exenteration.Journal of the colleges of medicine of South Africa · 2025Article
- Risk Factors for Orbital Invasion in Malignant Eyelid Tumors, Is Orbital Exenteration Still Necessary?Journal of clinical medicine · 2024Article
- Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances.Journal of ophthalmology · 2024Article
- A registration trend in eyelid skin cancers and associated risk factors in Iran, 2005-2016.BMC cancer · 2023Article
- Review
- Primary cemiplimab treatment for orbital squamous cell carcinoma is effective and may alleviate the need for orbital exenteration.Eye (London, England) · 2023Article
- A Systematic Review Article on Orbital Exenteration: Indication, Complications and Reconstruction Methods.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
- Simple, but effective: Nasal splinting for airway securement in free flap reconstruction following orbital exenteration.Head & neck · 2021Article
- Efficacy and safety of an artificial dermal graft for the reconstruction of exenterated sockets: a preliminary report.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Skull Base Invasion Patterns of Malignant Head and Neck Tumors: A Neurosurgical Perspective.Journal of neurological surgery. Part B, Skull base · 2021Article
- Gamma Knife Stereotactic Radiosurgery for Conjunctival Squamous Cell Carcinoma Invading the Anterior Orbit: A Case Series.Ocular oncology and pathology · 2021Article
- Systemic acitretin in the management of periocular squamous cell carcinoma.BMJ case reports · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
PurposeTo describe prognostic factors and survival outcomes in patients who underwent orbital exenteration for periocular non-melanoma cutaneous malignancies.MethodsThe authors performed an institutional review board-approved retrospective review of all patients who underwent orbital exenteration for non-melanoma periocular cutaneous malignancies at a tertiary care hospital system over a 10-year period. Patient demographics, tumor, and treatment data were recorded. Survival outcomes included disease-free survival (DFS) and overall survival (OS). Log-rank tests were used to test for difference in survival curves among various potential prognostic indicators, and multivariate analysis was performed using Cox's proportional hazards model.ResultsForty-nine patients with an average age of 70.3 years were followed with a median follow-up of 17.5 months. At 2 years the OS was 78% while the DFS was 61%. The mean DFS for basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and sebaceous gland carcinoma (SGC) were 52.6, 39.2 and 28.1 months, respectively. Multivariate analysis demonstrated that only positive final surgical margin was predictive of worse outcome (P=0.002). Recurrences were most frequent in the first 2 years.ConclusionsDespite the relatively more aggressive nature of periocular malignancies that have invaded the orbit, orbital exenteration offers an overall 2-year DFS of ~60%. BCC had the greatest mean survival time, however this was not statistically significant. We found worse prognosis with positive final surgical margins and recommend a multidisciplinary surgical approach to achieve complete resection when indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.